Oritavancin Diphosphate
FDA-approved product (powder, intravenous), marketed as Kimyrsa, Orbactiv.
- Registered studies
- 7
- Lab records
- 2
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Infection
- Skin disease caused by bacterial infection
- Soft Tissue Infections
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Glycopeptide antibacterials
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01XA05
Repurposing investigation
Oritavancin Diphosphate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli72.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae75.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
7registered studies name this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 2 of 2 lab records
Show the 2 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Oritavancin Diphosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Galantamine HydrobromideExisting use: Alzheimer disease, Dementia89.6% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more69.3% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives68.0% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- ElvitegravirExisting use: HIV infection, HIV-1 infection, Viral disease60.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more57.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm56.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more56.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome56.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more54.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia52.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- VoclosporinExisting use: Immune system disease, Lupus nephritis52.2% AI-predicted activityagainst K. pneumoniae28 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients
NCT03873987 · start 2019-07-16
Registered record
- Registry ID
- NCT03873987
- Conditions
- Acute Bacterial Skin and Skin Structure Infection
- Interventions
- Current Formulation of Oritavancin; Kimyrsa
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2019-07-16
- Completion
- 2019-09-04
- Enrolment
- 102
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Bacterial Skin and Skin Structure InfectionInterventionCurrent Formulation of Oritavancin; KimyrsaPhasePhase 1Registry statusCompletedDrug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects
NCT02340988 · start 2015-04
Registered record
- Registry ID
- NCT02340988
- Conditions
- Healthy
- Interventions
- Single-Dose IV Oritavancin Diphosphate and Warfarin; Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-04
- Completion
- 2015-09
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionSingle-Dose IV Oritavancin Diphosphate and Warfarin; Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dosePhasePhase 1Registry statusCompletedOpen Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections
NCT02134301 · start 2014-05
Registered record
- Registry ID
- NCT02134301
- Conditions
- Gram-positive Bacterial Infections
- Interventions
- Oritavancin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-05
- Completion
- 2025-11-04
- Enrolment
- 41
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGram-positive Bacterial InfectionsInterventionOritavancinPhasePhase 1Registry statusCompletedOpen Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers
NCT01784536 · start 2013-01
Registered record
- Registry ID
- NCT01784536
- Conditions
- Healthy
- Interventions
- Single-Dose IV Oritavancin Diphosphate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-01
- Completion
- 2013-03
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionSingle-Dose IV Oritavancin DiphosphatePhasePhase 1Registry statusCompletedA Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
NCT01762839 · start 2012-12-27
Registered record
- Registry ID
- NCT01762839
- Conditions
- Healthy
- Interventions
- Single-Dose IV Oritavancin Diphosphate; Placebo; Moxifloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-12-27
- Completion
- 2013-02-11
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionSingle-Dose IV Oritavancin Diphosphate; Placebo; MoxifloxacinPhasePhase 1Registry statusCompletedOritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
NCT01252719 · start 2010-12
Registered record
- Registry ID
- NCT01252719
- Conditions
- Wound Infection; Abscess; Systemic Inflammation; Cellulitis
- Interventions
- Single-Dose IV Oritavancin Diphosphate; IV Vancomycin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-12
- Completion
- 2012-11-30
- Enrolment
- 968
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionWound Infection; Abscess; Systemic Inflammation; CellulitisInterventionSingle-Dose IV Oritavancin Diphosphate; IV Vancomycin; PlaceboPhasePhase 3Registry statusCompletedOritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
NCT01252732 · start 2010-12
Registered record
- Registry ID
- NCT01252732
- Conditions
- Wound Infection; Abscess; Systemic Inflammation; Cellulitis
- Interventions
- Single-Dose IV Oritavancin Diphosphate; IV Vancomycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-12
- Completion
- 2013-06
- Enrolment
- 1,019
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionWound Infection; Abscess; Systemic Inflammation; CellulitisInterventionSingle-Dose IV Oritavancin Diphosphate; IV VancomycinPhasePhase 3Registry statusCompleted